We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




POC Glucose Monitoring Devices Market to Reach USD 2 Billion in 2022

By LabMedica International staff writers
Posted on 04 Apr 2018
The global POC blood glucose monitoring devices market is expected to reach USD 2.03 billion in 2022, driven mainly by public and private initiatives to reduce diabetic cases. More...
However, the high cost associated with diabetes management is one of the major factors hindering the market growth.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Most POC blood glucose monitoring devices manufactured by global and local players are cost-efficient. However, the cost associated with diabetes management in high, resulting in out-of-pocket expenditure for consumables used in POC blood glucose monitoring devices. These consumables, including blood glucose test strips, reagents, and cassettes are expensive and are required on a daily basis. Moreover, an invasive device such as lancet needs to be purchased separately along with the POC blood monitoring devices, resulting in additional cost being incurred.

Of late, there has been a paradigm shift to non-invasive products in the POC blood glucose monitoring devices market. Non-invasive POC blood glucose monitoring devices are hand-held units that offer a number of benefits over finger prick glucose test, such as helping to avoid finger prick and providing a convenient, easy to read large number display. Non-invasive POC blood glucose monitoring devices can also track patient compliance and allow multiple tests to be run in order to allow healthcare providers to provide adequate therapeutic decisions.

Related Links:
Research and Markets


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.